1691 – PromarkerD testing in patients with type 2 diabetes to determine the risk of developing diabetic kidney disease

Page last updated: 15 March 2023

Application Detail

Description of Medical Service

PromarkerD is a blood test designed to predict the risk of developing diabetic kidney disease (DKD) or progression of DKD in patients with type-2 diabetes (T2D).The test measures three plasma protein biomarkers (ApoA4, CD5L and IBP3) which are found in the blood, combined with clinical factors (age, HDL-cholesterol, kidney function) to generate prognostic risk scores for DKD in patients with T2D. The concentrations of the biomarkers, along with the clinical factors, are entered into the PromarkerD Hub, a static proprietary software algorithm which characterises patients as low-risk, moderate-risk, or high-risk of developing DKD.

Description of Medical Condition

Diabetic Kidney Disease (DKD) is a type of kidney disease caused in patients with diabetes. The kidneys are the body’s filtration system, removing waste and extra water from the blood. They also produce hormones and help to control blood pressure. When the kidneys are damaged, they no longer function effectively causing waste to build up leading to a range of health problems.

Reason for Application

New MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1096 KB)
Application Form (Word 159 KB)

Consultation Survey

Consultation Survey (PDF 692 KB)
Consultation Survey (Word 72 KB)

PASC Consultation
Consultation closed

MSAC Consultation
MSAC consultation input closed Friday, 7 October 2022.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (PDF 2231 KB)
PICO Confirmation (Word 1084 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 600 KB)
Public Summary Document (Word 147 KB)

Meetings for this Application


9-10 December 2021


6-7 October 2022


24-25 November 2022